The effect of administration of aprotinin, a serine esterase inhibitor capable of inactivating kallikrein, on the extent and severity of acute myocardial is chemic injury and subsequent necrosis, was studied in 25 patients. Another group of 25 patients who did not receive aprotinin served as a control group. We administered 100,000 kallikrein inhibitor units (KIU) of aprotinin as a bolus dose, followed by a continuous infusion (4 ml/min) that contained 10,000 KIU/kg in 240 ml of dextrose/water solution, to all 25 patients admitted to the hospital within 30 to 60 minutes after the onset of acute myocardial ischemia.
To measure the effect of aprotinin, three parameters were studied; the sum of S-T segment elevations (ΣST), the development of Q waves, and the predic tion of infarct size by measuring the disappearance rate of creatine phosphoki nase (MB CPK isoenzyme).
The average ΣST in the treated group decreased from 40.5 ± 7.00 mv to 12.95 ± 4.60 mv (P < 0.01); in contrast the control group's ΣST did not change significantly, from 54.25 ± 8.02 to 51.7 ± 6.8. Deeper Q waves evolved in the control group compared to the treated group: ΔQ (6 hours) = 1.0 ST (15 min) + 1.19 (25 patients, r = 0.78); and in the treated group ΔQ (6 hours) = 0.66 ST (15 min) + 0.91 (25 patients, r = 0.65) (P < 0.025).
In the control group the estimated infarct size was 57.4 ± 4 CPK-gram- equivalents (CPK-g-Eq). There was significantly less damage in the treated group: 19 ± 2 CPK-g-Eq (P < 0.01). Thus we conclude that aprotinin dimin ishes myocardial damage.
Get full access to this article
View all access options for this article.
References
1.
Braunwald, E. , Maroko, P.R.: The reduction of infarct size—An idea whose time (for testing) has come. Circulation, 50: 206, 1974.
2.
Diaz, P.E., Maroko, P.R.: The effects of aprotinin on myocardial ischemic injury following experimental coronary artery occlusion. Clin. Res., 23: 180A, 1975 (abstr.).
3.
Diaz, P.E., Fishbein, M.C., Davis, M.A., et al.: Effect of the kallikrein inhibitor aprotinin on myocardial ischemic injury after coronary occlusion in the dog. Am, J, Cardiol, 40: 541, 1977.
4.
Maroko, P.R. , Libby, P., Covell, J.W., et al.: Precordial S-T segment elevation mapping: An atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions . Am, J, Cardiol, 29: 223, 1972.
5.
Hillis, L.D. , Askenazi, J., Braunwald, E., et al.: Use of changes in the epicardial QRS complex to assess interventions which modify the extent of myocardial necrosis following coronary artery occlusion. Circulation , 54: 591, 1976.
6.
Sobel, B.E., Breshnahan, G.F., Shell, W.E., et al.: Estimation of infarct size in man and its relation to prognosis . Circulation, 46: 640, 1972.
7.
Shell, W.E., Kjekshus, J.K., Sobel, B.E.: Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase (CPK) activity. J. Clin. Invest., 50: 2614, 1971 .
8.
Wolfson, S., Heinle, R.A., Herman, M.V., et al.: Propranolol and angina pectoris. Am, J, Cardiol , 18: 345, 1966.
Libby, P., Maroko, P.R., Covell, J.W., et al.: The effects of practolol on the extent of myocardial ischemic injury following experimental coronary occlusion and its effects on ventricular function in the normal and ischemic heart. Cardiovasc. Res. , 7: 167, 1973.
11.
Sommers, H.M. , Jennings, R.B.: Ventricular fibrillation and myocardial necrosis after transient ischemia. Arch. Intern. Med., 129: 780, 1972.
12.
Maroko, P.R. , Bernstein, E.F., Libby, P., et al.: Effects of intra-aortic balloon counterpulsation on the severity of myocardial ischemic injury following actue coronary occlusion: Counterpulsation and myocardial injury. Circulation, 45: 1150, 1972.
13.
Spotnitz, H.M. , Covell, J.W., Ross, J., Jr., et al.: Left ventricular mechanics and oxygen
14.
consumption during arterial counterpulsation. Am. J. Physiol. , 217: 1352, 1969.
15.
Braunwald, E., Maroko, P.R.: Intra-aortic balloon counterpulsation. An assessment. Ann. Intern. Med., 76: 659, 1972.
16.
Maroko, P.R. , Libby, P., Ginks, W.R., et al.: Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis . J. Clin. Invest., 51: 2710, 1972.
17.
Ginks, W.R. , Sybers, H.D., Maroko, P.R., et al.: Coronary artery reperfusion. II. Reduction of myocardial infarct size at one week after the coronary occlusion . J. Clin. Invest., 51: 2717, 1972.
18.
Favaloro, R.G. : Surgical treatment of coronary arteriosclerosis by the saphenous vein graft technique. Am. J. Cardiol., 28: 493, 1971.
19.
Bloor, C.M. , White, F.C.: Coronary artery reperfusion: Early effects on coronary hemodynamics. Am. J. Cardiol., 31: 121, 1973.
20.
McNamara, J.J. , Soeter, J.R., Suehiro, G.T., et al.: Myocardial viability after transient ischemia. Am. J. Cardiol., 31: 146, 1973 (abstr.).
21.
Bresnahan, G.F., Shell, W.E., Ross, J., Jr., et al.: Deleterious effects of reperfusion in evolving myocardial infarction. Circulation, 46(suppl II): 13, 1972.
22.
Banka, V.S. , Chadda, K.D., Meister, S.G., et al.: Limitation of revascularization in restoration of regional contraction abnormalities produced by coronary occlusion. Am. J. Cardiol., 31: 118, 1973 (abstr.).
23.
Epstein, S.E. , Kent, K.M., Goldstein, R.E., et al.: Reduction of ischemic injury by nitroglycerin during acute myocardial infarction. N. Engl. J. Med., 292: 29, 1975.
24.
Flaherty, J.T. , Reid, P.R., Kelly, D.T., et al.: Intravenous nitroglycerine in acute myocardial infarction. Circulation, 51: 132, 1975.
25.
Come, P.C., Flaherty, J.T., Baird, M.G., et al.: Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction. N. Engl. J. Med., 293: 1003, 1975.
26.
Borer, J.S. , Redwood, D.R., Levitt, B., et al.: Reduction in myocardial ischemia with nitroglycerin or nitroglycerin plus phenylephrine administered during acute myocardial infarction. N. Engl. J. Med., 293: 1008, 1975.
27.
Maroko, P.R. , Libby, P., Sobel, B.E., et al.: Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion . Circulation, 45: 1160, 1972.
28.
Morgan, H.E. , Henderson, J.J., Regen, D.M., et al.: Regulation of glucose uptake in muscle. I. The effects of insulin and anoxia on glucose transport and phosphorylation in the isolated perfused heart of normal rats. J. Biol. Chem. , 236: 253, 1961.
29.
Weissler, A.M. , Kruger, F.A., Baba, N., et al.: Role of anaerobic metabolism in the preservation of functional capacity and structure of anoxic myocardium. J. Clin. Invest., 47: 403, 1968.
30.
Scheuer, J., Stezoski, S.W.: Protective role of increased myocardial glycogen stores in cardiac anoxia in the rat. Circ. Res., 27: 335, 1970.
31.
Owen, P., Thomas, M., Opie, L.: Relative changes in free-fatty-acid and glucose utilization by ischemic myocardium after coronary artery occlusion. Lancet, 1: 1187, 1969.
32.
Regen, D.M. , Davis, W.W., Morgan, H.E., et al.: The regulation of hexokinase and phosphofructokinase activity in heart muscle. J. Biol. Chem. , 239: 43, 1964.
33.
Wildenthal, K., Mierzwiak, D.S., Mitchell, J.H.: Acute effects of increased serum osmolarity on left ventricular performance. Am. J. Physiol., 216: 898, 1969.
34.
Randle, P.J. , Garland, P.B., Hales, C.N., et al.: The glucose fatty-acid cycle: Its role in insulin sensivity and the metabolic disturbance of diabetes mellitus . Lancet, 1: 785, 1963.
35.
Sodi-Pallares, D., Bisteni, A., Medrano, G.A., et al.: The repolarizing treatment in cardiovascular conditions: Experimental basis and clinical applications, in Electrolytes and Cardiovascular Diseases. Vol. 2. Edited by E. Bajusz.Baltimore, Williams & Wilkins, 1965, pp. 198-238.
36.
McLeod, D.P. , Daniel, E.E.: Influence of glucose on the trans-membrane action potential of anoxic papillary muscle. J. Gen. Physiol. , 48: 887, 1965.
37.
Sodi-Pallares, D., Ponce de Leon, J., Bisteni, A., et al.: Potassium, glucose and insulin in myocardial infarction. Lancet, 1: 1315, 1969.
38.
Mittra, B.: Potassium, glucose and insulin in treatment of myocardial infarction. Lancet, 2: 607, 1965.
39.
Lal, H.B., Carell, R.K.: Observations of 400 cases of acute myocardial infarction treated with insulin, potassium and dextrose infusions. Ind. J. Med. Res., 56(suppl): 1120, 1968.
40.
Fletcher, G.F. , Hurst, J.W., Schlant, R.C.: "Polarizing" solution in patients with acute myocardial infarction: A double blind study with negative results. Am. Heart. J., 75: 319, 1968.
41.
Report by the Medical Research Council Working Party on the treatment of myocardial infarction: Potassium, glucose and insulin treatment for acute myocardial infarction. Lancet, 2: 1355, 1968.
42.
Maroko, P.R. , Libby, P., Bloor, C.M., et al.: Reduction by hyalouronidase of myocardial necrosis following coronary artery occlusion. Circulation, 46:430, 1972.
43.
Britton, R.C. , Habif, D.V.: Clinical uses of hyaluronidase: A current review. Surgery, 33: 917, 1953.
44.
Moore, D.C. : An evaluation of hyaluronidase in local and nerve block analgesia: A review of 159 cases. Anesthesiology , 11: 470, 1950
45.
Schwartzman, J.: Hyaluronidase: A review of its therapeutic use in pediatrics. J. Pediat., 38: 491, 1951.
46.
Meyer, K.: Biological significance of hyaluronic acid and hyaluronidase. Physiol. Rev., 27: 335, 1947.
47.
Hechter, O. : Mechanisms of spreading factor action. Ann. N.Y. Acad. Sci., 52: 1028, 1950.
48.
Szabo, G., Magyar, S.: Effect of hyaluronidase on capillary permeability, lymph flow and passage of dyelabeled protein from plasma to lymph. Nature (Lond.), 182: 377, 1958.
49.
Libby, P., Maroko, P.R., Bloor, C.M., et al.: Reduction of experimental myocardial infarct size by corticosteroid administration. J. Clin. Invest., 52: 599, 1973.
50.
Spath, J.A. , Jr., Lane, D.L., Lefer, A.M.: Protective action of methyl-prednisolone on the myocardium during experimental myocardial ischemia in the cat. Circ. Res., 35: 44, 1974.
51.
Maroko, P.R. , Carpenter, C.B.: Reduction in infarct size following acute coronary occlusion by the administration of cobra venom factor. Clin. Res., 22: 289A, 1974 (abstr.).
52.
Kjekshus, J.K. , Mjos, O.D.: Effect of inhibition of lipolysis on infarct size after experimental coronary artery occlusion. J. Clin. Invest., 52: 1770, 1973.
53.
Liedtke, A.J. , Nellis, S.H., Neely, J.R., et al.: Effects of treatment with pyruvate and tromethamine in experimental myocardial ischemia. Circ. Res., 39: 378, 1976.
54.
Stormorken, H., Gloennaess, H., Laake, K.: Interrelations between the clotting and kinin systems. Activation of factor VII involving prekallikrein-kallikrein. A review . Haemostasis, 2: 245, 1974.
55.
Back, N.: The patho-physiologic and clinical implications of the fibrinolysin and kallikrein-kinin systems in Proteases and Anti-proteases in Cardiology. Edited by L. Donatelli, A. Marino, G. L. Haberland, et al. Stuttgart, New York, F. K. Schattaver Verlag, 1969, p. 25.
56.
Cotran, R.S. , Majno, G.: A light and electron microscopic analysis of endothelial injury. Ann. N. Y. Acad. Sci., 116: 750, 1964.
57.
Leaf, A.: Cell swelling: A factor in ischemic tissue injury. Circulation , 28: 455, 1973.
58.
Back, N., Steger, R.: Effect of inhibitors in kinin-forming activity of proteases. Fed. Proc., 27: 96, 1968.
59.
Schnells, G.: Inhibition of cardiotoxic and other destructive actions of proteolytic enzymes by an enzyme inactivator in vivo, in New Aspects of Trasylol Therapy. Vol. 8. Edited by M. Cantin, G. L. Haberland, G. Schnells, et al. Stuttgart, New York, F. K. Schattauer Verlag, 1975, p. 25.
60.
Movat, H.Z. , Steinberg, S.G., Habal, R.M., et al.: Demonstration of a kiningenerating enzyme in the lysosomes of human polymorphonuclear leukocytes. Lab. Invest., 29: 669, 1973.
61.
Lefer, A.M., Spath, J.A., Jr.: Protective effect of protease inhibition in myocardial ischemia , in New Aspects of Trasylol Therapy. Vol. 8. Edited by M. Cantin, G. L. Haberland, G. Schnells , et al. Stuttgart, New York , F. K. Schattauer Verlag, 1975, p. 311.
62.
Glenn, T., Tauber, P.F., Miller, A.G., et al.: Alterations of the hemodynamic and biochemical sequelae associated with acute coronary artery ligation with aprotinin, in New Aspects of Trasylol Therapy. Vol. 8. Edited by M. Cantin, G. L. Haberland, G. Schnells, et al. Stuttgart, New York, F. K. Schattauer Verlag, 1975, p. 329.
